Epic Wholesalers LLC -dba-Epic Peptides Lab

Certificate of Analysis · Lot release

www.epicpeptideslab.com

Certificate no.

PL-26-00170

Verification key

L8S6UU5X

Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab

CJC-1295 noDAC+Ipamorelin 15 mg Pen

Lot PL-2610-048 · Solution · Label claim 15 mg/mL

Tested in-house by PrymaLab

In-house analytical result,
not an independent third-party test

Lot / batch number

PL-2610-048

Date made

2026-10-02

Date of analysis

2026-10-05

Date issued

2026-10-19

Retest / expiry

2028-10-02

Units in lot / sampled

255 / 2

Storage

—

Certificate type

Lot COA, 2 pages

Compound

CJC-1295 (no DAC) / Ipamorelin Blend

Modified GRF(1–29) + Ipamorelin co-lyophilized 1:1 blend

CAS number

863288-34-0 · 170851-70-4

Molecular formula

—

Theoretical mass (avg.)

3,367.90 · 711.85 Da (CJC-1295 noDAC / Ipamorelin)

Composition and sequences

CJC-1295 noDAC: 30-aa GHRH analog · Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH2

Purity · RP-HPLC, area %

99.45%

Lowest component (CJC-1295 noDAC) • specification ≥ 99.0% for every component

Identity · Components Confirmed

2 / 2

Components confirmed by LC-MS within ± 1.0 Da: 3,368.10 / 711.81 Da

Overall conclusion

PASS

Meets every specification for the tests performed

Test	Method	Specification	Result	Conclusion
CJC-1295 noDAC: purity · largest impurity · mass	RP-HPLC 214 nm (area%); LC-MS, ESI+	≥ 99.0% · ≤ 1.0% · ± 1.0 Da	99.45% · 0.34% · 3,368.10 Da	PASS
Ipamorelin: purity · largest impurity · mass	RP-HPLC 214 nm (area%); LC-MS, ESI+	≥ 99.0% · ≤ 1.0% · ± 1.0 Da	99.79% · 0.08% · 711.81 Da	PASS
Assay (total blend)	Assay vs label claim	14.25–15.75 mg/mL	15.23 mg/mL	PASS
Bacterial endotoxin	LAL, kinetic	≤ 5.0 EU/mg	0.229 EU/mg	PASS
Sterility	USP <71>, 14-day	No growth	No growth	PASS

1HPLC chromatogram

Data file: PL-2610-048-HPLC.raw · Column C18, 150 × 4.6 mm · UV 214 nm

Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-048-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot. Area % is per component (each component main peak + its impurities = 100%).

Epic Wholesalers LLC -dba-Epic Peptides Lab

Certificate of Analysis · continued

CJC-1295 noDAC+Ipamorelin 15 mg Pen · Lot PL-2610-048 · Certificate PL-26-00170

Lot PL-2610-048

Method, peak table and approval

2HPLC method · PL-2610-048-HPLC.raw

Instrument

Waters Alliance e2695

Data System

Empower 3

Detector

UV absorbance

Detection Wavelength

214 nm

Column

C18, 150 × 4.6 mm, 3.5 µm

Mobile Phase A

0.1% TFA in water

Mobile Phase B

0.1% TFA in MeCN

Gradient

5–95% B over 25 min (linear)

Flow Rate

1.0 mL/min

Column Temperature

40 °C

Injection Volume

10 µL

3Gradient program

Time (min)	% A	% B
0.0	95	5
25.0	5	95

4Peak table

Peak	RT (min)	Area	Area %
1	14.20 †	—	0.04
2	14.90 †	—	0.34
3	15.74	—	99.45
4	16.30 †	—	0.17
5	16.80 †	—	0.07
6	18.10	—	99.79
7	18.90 †	—	0.08
8	19.50 †	—	0.06
Total		—	100.00 per component

Main peaks: 3 CJC-1295 noDAC · 6 Ipamorelin; all other peaks are the assigned impurities of the neighbouring component · area % within each component (main + impurities = 100% per component) · † nominal reference RT · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument

Waters SQD

Ionization / Mode

ESI, positive

Deconvoluted Mass

3,368.10 / 711.81 Da

Theoretical Mass

3,367.90 / 711.85 Da

Order

CJC-1295 noDAC / Ipamorelin

Difference

+0.20 / −0.04 Da

Data File

PL-2610-048-MS.d

Acceptance

Within ± 1.0 Da (each component)

6Additional tests

Test	Performed by	Date	Report / file
Assay vs label claim	PrymaLab Analytical	2026-10-05	—
Endotoxin (LAL, kinetic)	PrymaLab Analytical	2026-10-05	—
Sterility (USP <71>, day-14 read-out)	PrymaLab Analytical	2026-10-19	—

A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-19

S. Calloway
Reviewer · checked against raw data
Date: 2026-10-19

M. Phelps
Lab Director · approved for release
Date: 2026-10-19